Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 11/20 | 0.38 |
| ▸ | CCNC | P24863 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406083 | 0.90 | HRH4 (0.56) | HRH4HTR6SOS1THRB | |
| SCHEMBL404682 | 0.88 | HRH4 (0.54) | HRH4HTR6SOS1 | |
| SCHEMBL12224915 | 0.87 | HRH4 (0.51) | HRH4SOS1THRB | |
| SCHEMBL405989 | 0.86 | HRH4 (0.57) | HRH4HTR6SOS1 | |
| SCHEMBL406287 | 0.86 | HRH4 (0.54) | HRH4HTR6SOS1 | |
| SCHEMBL462918 | 0.84 | HRH4 (0.50) | HRH4HTR6SOS1 | |
| Hydrochloric Acid SCHEMBL438156 | 0.83 | HRH4 (0.49) | HRH4HTR6SOS1 | |
| SCHEMBL462902 | 0.82 | HRH4 (0.50) | HRH4HTR6SOS1 | |
| SCHEMBL12224888 | 0.81 | HRH4 (0.38) | HRH4SOS1CCNCCDK8 | |
| SCHEMBL404754 | 0.81 | HRH4 (0.54) | HRH4HTR6SOS1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HTR6 111/4885SOS1 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.